Skip to content

Propranolol for Protracted Labor

Propranolol for Prolonged Labor: A Randomized Controlled Trial (PRO-Labor Trial)

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04741698
Acronym
PRO-Labor
Enrollment
80
Registered
2021-02-05
Start date
2021-07-27
Completion date
2022-07-01
Last updated
2022-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Dystocia, Labour;Obstructed

Brief summary

Induction of labor is one of the most common procedures performed on labor and delivery. In the United States, more than 20 percent of pregnant women undergo an induction of labor \[1\]. There is data from small, randomized studies that demonstrates the effectiveness of propranolol, a non-selective beta-blocker, for labor augmentation. This literature suggests a decrease in the amount of time to delivery and a possible reduction in cesarean section rates when propranolol is used in conjunction with oxytocin for induction of labor compared to oxytocin alone \[2-8\]. Alpha- and beta-adrenergic receptors have been identified in the human myometrium. Propranolol has been shown in studies to enhance uterine contractions and may be a useful tool in this population of women. Therefore, the purpose of this study is to assess whether the administration of propranolol at time of labor dystocia reduces time to delivery.

Detailed description

All cervical ripening will be performed in the labor and delivery unit; continuous fetal heart rate and uterine activity will be monitored in all patients. Cervical dilation is assigned by admitting physicians. Sonography will be performed to document fetal presentation. At the time of prolonged labor, patients meeting inclusion criteria and no exclusion criteria will be consented. There will be no monetary incentives for participation. Patients will be randomized to either Propranolol 2mg of IV or expectant management at the time of induction. Maternal vitals will be collected per standard labor management. Episodes of uterine activity that are deemed excessive by the physician will be treated with a standard combination of maneuvers that included a change in maternal position, oxygen administration, and terbutaline 250 µg subcutaneously. Persistent abnormal fetal heart rate patterns resulted in intervention by removing the patient from the study. Urgent cesarean delivery is defined as a cesarean delivery performed during the ripening process for abnormal fetal heart rate that did not respond to standard maneuvers.

Interventions

DRUGPropranolol

Propranolol 2mg IV

Sponsors

Christiana Care Health Services
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* ≥18 years of age * full term (≥37 weeks) gestations determined by routine obstetrical guidelines * singleton gestation in cephalic presentation * Intact membranes * Bishop score of ≤6 and cervical dilation ≤2cm

Exclusion criteria

* Preterm gestation * Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate * multiparous women * Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block) * Known hypersensitivity to propranolol * Maternal bradycardia (HR \<60bpm) * Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control * Systolic blood pressure \<90 mmHg, or diastolic blood pressure \<50 mmHg * Receiving other beta blocker * Moderate or severe asthma: as this is a contraindication to beta blocker use * Any contraindication to a vaginal delivery * fetal demise * Multifetal gestation * major fetal anomaly * prior uterine surgery, previous cesarean section * women with HIV, hepatitis C, hepatitis B, and women with medical conditions requiring an assisted second stage * Additional

Design outcomes

Primary

MeasureTime frameDescription
time to deliveryNumber of hours from induction to delivery of neonate; up to 72 hours.The primary outcome is time to delivery (hours) defined as time from initiation of induction method to delivery time, regardless of mode of delivery.

Secondary

MeasureTime frameDescription
maternal length of stayFrom time of admission to time of hospital discharge; an average of two daysfrom time of admission to discharge
Maternal Bradycardia eventat time of deliverybradycardia alert during labor
ChorioamnionitisAt time of deliverydefined by the presence of maternal fever ≥100·4°f in the presence of maternal or fetal tachycardia or fundal tenderness
neonatal admission to ICUAt time of deliveryNICU admission
cesarean delivery rateAt time of deliveryrate of cesarean delivery
neonatal sepsisat time of deliveryCulture proven-presumed neonatal sepsis
Neonatal blood transfusionFrom time of delivery to time of hospital discharge; up to 6 weeksNeonatal blood transfusion
Hypoxic ischemic encephalopathythrough study completion, an average of 1 yearneonatal HIE
Severe respiratory distress syndromeat time of deliverydefined as intubation and mechanical ventilation for a minimum of 12 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026